Current approaches to treat Phase II ROP include laser treatment to ablate regions of the peripheral avascular retina [3] or intravitreal administration of agents that reduce the bioactivity of vascular endothelial growth factor (VEGF) [4]. Here, VEGFA is linked to retinopathy of prematurity.